ERBB2 and breast cancer: Of them 26% had high TILs, 48% received RT, 97% received chemotherapy, all HER2+ BC patients received HER2‐directed therapy and all HER2+ BC that were also hormone receptor positive (HR+) received endocrine therapy (ET).